hpv vaccine introduction in africa: early lessons...
TRANSCRIPT
HPV vaccine introduction in Africa: Early lessons learned
Regional Conference on New Opportunities and Innovations in Cervical Pre-Cancer Screening and Treatment, Lusaka, Zambia
Chilunga Puta, PhD D. Scott LaMontagne, PhD Vivien Tsu, PhD 19 June 2014
Background
• Two vaccines (2 or 3 doses) – bivalent (GSK) and quadrivalent (Merck); both prequalified by WHO for 3 doses
• National introductions in Africa: Lesotho, Rwanda, South Africa, Uganda
• Demonstration and pilot projects in Africa: Botswana, Cameroon, Ghana, Kenya, Madagascar, Malawi, Mali, Mozambique, Niger, Nigeria, Sierra Leone, South Africa, Tanzania, Uganda, Zambia
• Worldwide, more than 50 countries have national HPV vaccine programs
• GAVI Alliance provides subsidized vaccine for low-income countries (countries pay US$0.20-$0.30/dose; GAVI pays rest of price)
Page 2
Evaluation sources
• Formal and informal evaluations • Literature review – several published papers • PATH experience – 4 rigorously evaluated demonstration
projects • Reports at national and regional meetings • Key aspects evaluated: coverage, feasibility, cost, acceptability
Page 3
Lessons can be grouped in 3 categories: • Operational • Community education and mobilization • GAVI-specific issues
Operational: Micro-planning and coordination
• Micro-planning • Should be done at local level and involve all key stakeholders
• Coordination • Strong coordination between health and education sectors is
essential, especially for school-based programs • Immunization program (EPI) usually takes lead, but other sectors
within MOH can be valuable partners (adolescent health, school health, reproductive health, non-communicable diseases)
• Good communication and cooperation between central and district levels are critical
• Nurse immunizers and community mobilizers are key personnel
Page 4
Operational: Service delivery design
• Venue • Several different delivery strategies have been successful • Schools effective, especially primary level when girls still attend • Schools and other outreaches require transport and, in some
places, allowances for staff • Health facilities – puts travel burden on families • Other community settings – good for education and simple
clinical interventions • Target population
• Can be defined by age, year of birth, or grade (class) in school • Easy to identify based on grade in school, but wide range of ages
in each grade • Variable feasibility when targeting age or year of birth
Page 5
Operational: Vaccination schedule
• Previous 3-dose schedule • Completion best if done within one school year • For school-based programs, must coordinate with holiday and
exam schedules • New 2-dose schedule – limited experience in Africa
• WHO recently determined there is sufficient evidence to switch from 3-dose to 2-dose, with minimum interval of 6 months and limited to girls less than 15 years at the time of the first dose
• Can also be annual schedule with dose 2 given 12 months after dose 1
• Timing • Pulsed services less disruptive than continuous • Short “mop-up” period useful for girls who missed dose
Page 6
Community: HPV vaccine acceptability high
6/24/2014
Page 7
Factor Girls Parents
Protection against cancer/vaccines good for health. √ √
Information received and understood. √ √
Direct communication by health workers, teachers, and community leaders. √ √
Messages reinforced by multiple, trusted sources. √ √
Endorsed by government, teachers, and community leaders. √
Absenteeism, insufficient information, lack of awareness. √
Concerns about new vaccines, vaccine safety, and side effects. √ √
References: LaMontagne 2011; Cover 2012; Bartolini 2012; Katahoire 2013; Paul 2011 (unpublished); Wamai 2012; Watson-Jones 2012.
Community: Tailored communication strategies
• Needs of different audiences: girls, parents, health workers, community leaders • Different questions • Different channels
• For parents in Uganda, talking with informed people in the community was more important than print materials or mass media messages (Galagan, 2013)
Page 8
Will it hurt?
Is it safe?
Why do girls need it?
Community: Tailored communication strategies
• Government endorsement is critical to success (national, district health officials, teachers)
• Timing varies by group:
Page 9
Community: Rumors and misinformation
• Create a strong communications team and develop a crisis response plan well in advance
• Train key spokespersons and assemble evidence in advance so response can be swift and persuasive
• Keep religious and community leaders and school officials involved from early on and continuously throughout—including those who represent ethnic, religious and political minorities
• Identify advocates who are knowledgeable and trusted by the community
• Don’t repeat the rumors and don’t criticize or stigmatize the rumor group or individual
Page 10
GAVI-specific lessons from demonstration projects
Achievements • Many more countries than
expected have applied and launched demonstration projects
• “Learn by doing” goal has been well accomplished
• Initial coverage data shows good acceptance
Challenges ? • District selection criteria and
constraints not well understood • Data on population and schools
not readily available • Insufficient time between years
1 and 2 to make adjustments • Confusion about program
guidelines • Budget rules not well
understood
Page 11
Many resources from WHO
• HPV Vaccine Introduction Clearing House
http://www.who.int/immunization/hpv/en/
• HPV vaccine introduction guide http://www.who.int/entity/immunization/hpv/plan/hpv_vaccine_intro_guide_c4gep_who_2013.pdf?ua=1
• Population estimates, 9-13 girls http://www.who.int/entity/immunization/monitoring_surveillance/Pop_year_age.zip?ua=1
• HPV vaccine communication http://apps.who.int/iris/bitstream/10665/94549/1/WHO_IVB_13.12_eng.pdf?ua=1
• Cervical cancer prevention and control costing tool (C4P)
http://www.who.int/entity/immunization/diseases/hpv/cervical_cancer_costing_tool/en/index.html
Page 12
Resources from PATH and others
• Practical experience guides for implementation and evaluation
http://www.rho.org/HPV-practical-experience.htm
• Lessons learned summaries http://www.rho.org/lessons-learned-
reports.htm
• Cervical cancer and HPV vaccine resource library, and Action Planner
www.rho.org
• Cervical Cancer Action Report Card http://cervicalcanceraction.org/pubs/pubs.php#reportcard
Page 13
Conclusions
• High uptake of HPV vaccine is achievable • Many delivery strategies are feasible; all need good planning,
coordination and evaluation • Vaccine is acceptable to communities, IF there are
• Tailored communication strategies that address information needs
• Visible government endorsement and support • Prompt attention to rumors and misinformation
• GAVI support is providing valuable opportunity to learn
Page 14
HPV vaccine represents incredible opportunity to protect future generations of women
from the scourge of cervical cancer
Thank you
Page 15
Chilunga Puta, PhD [email protected] http://www.path.org/our-work/cervical-
cancer.php www.rho.org